Below is a review of novel drug and biological products approved by the Food and Drug Administration (FDA) in 2024. The list includes several groundbreaking therapies that are expected to change the ...

Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Merck (MRK) to $113 from $123 and keeps an Equal Weight rating on the ...

We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Merck & Co., Inc.

Co Inc (NYSE:MRK) shares, reducing the pharmaceutical giant's price target from $130.00 to $122.00 while reaffirming a Buy rating on the stock. The revision by Guggenheim analyst is primarily due to ...

The dosing regimen for Winrevair is optimal for balancing safety and effectiveness in adults with PAH, according to clinical ...